Psyence Signs Letter of Intent with Australian CRO iNGENū
08 janv. 2023 19h00 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental...
Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
15 déc. 2022 08h47 HE
|
Psyence Group Inc.
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and...
Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor
14 déc. 2022 09h00 HE
|
Psyence Group Inc.
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
GOODMIND™ Available for Sale in the United Kingdom and Europe - Exclusive Distribution Agreement Concluded With This Works
29 nov. 2022 09h37 HE
|
Psyence Group Inc.
TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural...
Psyence Group Announces Strategic Private Placement
10 nov. 2022 07h00 HE
|
Psyence Group Inc.
TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
Psyence Group Completes Export of Psilocybin Mushrooms to Portugal
29 sept. 2022 07h00 HE
|
Psyence Group Inc.
TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has successfully exported medical grade...
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
22 sept. 2022 07h00 HE
|
Psyence Group Inc.
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in...
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
19 sept. 2022 07h00 HE
|
Psyence Group Inc.
TORONTO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
07 sept. 2022 11h00 HE
|
Psyence Group Inc.
TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural...
Psyence Group Corporate Update
02 juin 2022 07h00 HE
|
Psyence Group Inc.
Highlights: Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament HealthDr. Clive Ward-Able has been...